title: Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites.
abstract: OBJECTIVE
  To evaluate tumor response in patients with hypovascular liver metastases from the most common primary sites treated with chemoembolization.
  
  
  METHODS
  Chemoembolization was performed in 190 patients (five groups) who had hypovascular liver metastases from the colon (n = 66), breast (n = 40), uveal malignant melanoma (n = 20), pancreas (n = 48) and stomach (n = 16). Surgical resection of primary sites had been performed for all included patients. Tumor response, survival statistics from the first chemoembolization using Kaplan-Meier method and progression rate of embolized lesions were evaluated by analysis of variance with Tukey's post hoc test.
  
  
  RESULTS
  Multiple comparison between the groups showed no statistical significant difference in local tumor response (H: 9.23; p > 0.05). Survival indices of the patients, including survival rate, progression-free survival rate, median survival time and time to progression, demonstrated significant difference between the groups during the follow-up period (H: 9.7; p = 0.045). The progression rate of treated liver metastases from colon, breast, uvea, pancreas and stomach were 16.6, 17.5, 30.0, 25.0 and 32.0%, respectively (p = 0.002).
  
  
  CONCLUSIONS
  Hypovascular liver metastases treated with chemoembolization may demonstrate equal local response, but are significantly different in rate of progression and survival.
authors.affiliation: Department of Radiology, Marienhospital Osnabrueck, Bischofsstrasse 1, 49074 Osnabrueck, Germany. parvizfarshid@gmail.com
authors.forename: Parviz
authors.initials: P
authors.lastname: Farshid
authors.forename: Abbas
authors.initials: A
authors.lastname: Darvishi
authors.forename: Nagy
authors.initials: N
authors.lastname: Naguib
authors.forename: Babak
authors.initials: B
authors.lastname: Bazrafshan
authors.forename: Jijo
authors.initials: J
authors.lastname: Paul
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mbalisike
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Vogl
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000098:blood supply / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D019233:Retreatment; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome; D014604:Uveal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy
chemical_list: D000903:Antibiotics, Antineoplastic; D016685:Mitomycin